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Letter to the editor: Reconsidering the causality of TIA1 mutations in ALS 
  
Project Mine ALS Sequencing Consortium 
*A full list of consortium members appears at the end of this manuscript 
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In a recent study published in Neuron, Mackenzie and colleagues prioritised T cell-restricted 
intracellular antigen-1 (TIA1) as a novel amyotrophic lateral sclerosis (ALS) related gene. 
The authors state that their findings indicate a causal role for TIA1 in ALS/FTD, which has 
already been adopted in a resource frequently used in the clinic (Neuromuscular Disease 
Center). Although the biology of TIA1 is very appealing and the functional experiments 
have been well-performed, current guidelines stress that these experiments do not prove 
causality (MacArthur et al. 2014). Regarding the evidence that is provided for causality, we 
feel obliged to share concerns that affect the validity of the conclusion that TIA1 mutations 
cause ALS. In short, we argue that the presented pedigree merely yields TIA1 as a 
candidate gene. The subsequent burden analysis lacks crucial methodological details, is 
potentially flawed, yields inconclusive results and without a replication effort, 
rare TIA1 mutations cannot be regarded as causal in ALS. 
  
Mackenzie and colleagues performed whole exome sequencing in a single pair of second 
degree relatives. After filtering rare non-synonymous variants present in both relatives, 17 
genes containing variants remained. Five of the 17 genes were expressed in brain and were 
predicted deleterious (CADD score >20). Out of these 5 genes, the variant P362L in TIA1 
was picked as most interesting candidate. It affects a conserved residue and the variant was 
predicted to be possibly damaging or deleterious by several in silico prediction algorithms. 
It is important to note that 4 more candidate genes were present in this pedigree derived 
from these filtering steps, with similar predictions for deleteriousness and CADD scores.  In 
this context and without evidence for segregation, interesting observations, such as allele-
frequency in public databases, phylogenic conservation and pathogenicity in other diseases 
can be used to prioritise candidate genes, but do not prove causality. To justify claims of 
causality, the candidate gene needs to pass the threshold for multiple testing in robust 
association analyses (in both a discovery and replication phase). 
  
Mackenzie and colleagues indeed proceed with a burden analysis, where they present a p-
value for TIA1 variants in exon 11-13 (p = 8.7 x 10-6, SKAT-O adjusted for sex and age). It 
might be tempting to judge the evidence by this p-value alone (Leek and Peng 2015). 
However, we experienced difficulties in interpreting the p-value in the absence of 
methodological details. 
  
First, in order to correctly interpret the presented p-value, we would be very interested in 
the following methodological details: (1) which criteria were used to include variants in the 
burden analysis? (2) Were cases and controls matched for ancestry? Imperfect matching 
can severely inflate association statistics, especially in the analysis of rare variants (Do, 
Kathiresan, and Abecasis 2012). (3) Were related individuals excluded from the analysis? (4) 
Were any quality control measures performed? (5) Of the 3,036 controls, 959 are from a 
difference cohort and sequenced using a different technique (Sanger sequencing vs. next 
generation sequencing). Did the authors ensure that both methods were equally sensitive 
to detect all variants? Considering these methodological concerns, the interpretation of 
association analyes requires evidence of a well-behaved test-statistic (i.e. non-inflated QQ-
plot) that ensures known and unknown confounders have been addressed adequately.  
  
Second, it remains unclear how the authors derived a p-value of 8.7 x 10-6 , considering they 
detected 6 variant carriers among 1,039 patients and 0 variants among 3,036 controls. 
These numbers can be used to reconstruct their burden test using simulated data. Our 
simulation includes the same number of cases and controls, with identical allele-counts. 
The SKAT-O test yields a p-value of ~1.37 x 10-4. Alternative aggregation tests such as 
SKAT, Firth logistic regression and Fisher exact, yield similar p-values (R-script available on 
https://bitbucket.org/ProjectMinE/tia1). This is, of course, an approximation because we do 
not have the exact same covariate data. Permuting the test 10,000 times with respect to 
the covariates does not yield a p-value < 1.13 x 10-4. Without knowing the details of the 
burden test performed, the reported p-value of 8.7 x 10-6 might, therefore, be very well 
higher (i.e. less significant). 
  
Third, in the context of a discovery phase experiment, the presented p-value does not 
justify rejection of the null-hypothesis. If we assume adequate methodology, we interpret 
this p-value in the context of an exome-wide hypothesis-generating search because TIA1 
can only be regarded as a candidate gene at this point. Therefore, it requires a stringent 
multiple testing correction of at least 1.7 x 10-6 (0.05, Bonferroni corrected for 21,000 
protein-coding genes and 9,000 long noncoding RNA genes)(MacArthur et al. 2014). 
However, if a variety of tests and variant subsets have been considered, p < 5 x 10-7 is the 
recommended threshold (Do, Kathiresan, and Abecasis 2012). Furthermore, Mackenzie and 
colleagues only test variation within a specific domain of TIA1. Depending on the definition 
of a domain the number of domains in our genome far exceeds the number of 
genes(Sillitoe et al. 2015). Therefore, it can be argued that an even more stringent multiple 
testing correction is needed. The reported p-value does not meet any of these multiple 
testing criteria. 
  
Fourth, replication is required in order to claim causality. To our knowledge there are 3 
easily-available ALS-specific case-control cohorts (Table 1) including considerably more 
cases and controls than in the presented burden test. It is well-acknowledged that 
association analyses, such as the presented burden test, benefit from the largest number of 
cases and controls available to decrease the chances of both false negative and false 
positive results. We performed burden analysis on TIA1 exon 11-13 in the Project MinE 
Consortium dataset. Data acquisition and quality control has been described previously 
(Project MinE Consortium et al. 2017). We assumed the same filtering was performed as in 
the pedigree exomes that prioritised TIA1 as the candidate gene. We extracted 
heterozygous variants that alter the amino acid sequence, that were seen 2 or fewer times 
in ExAC and were not observed in the Exome Variant Server. This did not yield a significant 
result (p > 0.32; SKAT-O adjusted for first 10 principal components, sex and platform; ߣீ஼ ൌ1.01). We acknowledge that this burden test could still be underpowered and do not 
consider this as definite evidence that TIA1 mutations are not association with ALS. To 
increase power and provide a more definite answer, we strongly encourage the combined 
analysis of all available data for the region of interest (interpreted as discovery phase). 
  
 
  Method Cases Controls 
Cirulli et al. 2015 WES 2,869 6,405 
Kenna et al. 2016 WES 1,022 (FALS) 7,315 
Project MinE Consortium et al. 2017 WGS 4,389 1,846 
Table 1. WES = Whole Exome Sequencing, WGS = Whole Genome Sequencing, FALS = Familial ALS cases 
  
  
In conclusion, even though the extensive functional experiments performed by Mackenzie 
and colleagues shed light on the biological function of TIA1 and show that stress granule 
dynamics and phase separation may be a crucial aspect of ALS pathophysiology, there is 
currently insufficient genetic evidence to support a causal role for TIA1 mutations in ALS. 
We encourage research initiatives to provide robust genetic evidence before claiming 
causality. Therefore, we fully support the author's remark that future studies in ALS and 
FTD patient cohorts and control populations will be critical to evaluate the contribution of 
TIA1 in ALS/FTD. Until then, we would advise against routine screening of TIA1 mutations in 
ALS/ FTD patients in the clinic. 
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